August 10, 2021
J&J’s Ponvory May Be Late to the Multiple Sclerosis Market, but Doctors Still See Potential: Study
By: Beth Snyder Bulik
Johnson & Johnson’s Ponvory is the fourth in its class and the ninth branded oral drug in multiple sclerosis, and it hasn’t exactly sped out of the starting gate. But it’s off to a surprisingly good start when it comes to physician opinions, a survey found.
In a Spherix Global Insights survey, physicians projected a 4.5% market share for Ponvory six months from now. If they follow through, that would put Ponvory on par with Bristol Myers Squibb’s Zeposia, launched last June, which has a 4.1% projected share in January 2022, and in front of Novartis’ Mayzent at 3.3%, Spherix found…(read more)